Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 28 articles:
HTML format
Text format



Single Articles


    February 2017
  1. HUGEN N, Nagtegaal ID
    Distinct metastatic patterns in colorectal cancer patients based on primary tumour location.
    Eur J Cancer. 2017;75:3-4.
    PubMed     Text format    


  2. PAPAMICHAEL D, Aapro M
    Geriatric factors and outcomes in metastatic colorectal cancer.
    Eur J Cancer. 2017 Feb 10. pii: S0959-8049(16)32566.
    PubMed     Text format    


    January 2017
  3. MODEST DP, Neumann UP, Pratschke J
    FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Eur J Cancer. 2017 Jan 9. pii: S0959-8049(16)33085.
    PubMed     Text format    


  4. SARTORE-BIANCHI A, Pietrantonio F, Amatu A, Milione M, et al
    Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Eur J Cancer. 2017;71:43-50.
    PubMed     Text format     Abstract available


    December 2016
  5. CREMOLINI C, Casagrande M, Loupakis F, Aprile G, et al
    Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Eur J Cancer. 2016 Dec 13. pii: S0959-8049(16)32534.
    PubMed     Text format     Abstract available


    November 2016
  6. HOLCH JW, Ricard I, Stintzing S, Modest DP, et al
    The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Eur J Cancer. 2016;70:87-98.
    PubMed     Text format     Abstract available


  7. DUCREUX M, Pignon JP
    Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?
    Eur J Cancer. 2016;69:178-179.
    PubMed     Text format    


  8. APARICIO T, Gargot D, Teillet L, Maillard E, et al
    Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Eur J Cancer. 2016 Nov 5. pii: S0959-8049(16)32475.
    PubMed     Text format     Abstract available


  9. ROTTENBERG Y, Ratzon NZ, Cohen M, Hubert A, et al
    Unemployment risk at 2 and 4 years following colorectal cancer diagnosis: a population based study.
    Eur J Cancer. 2016;69:70-76.
    PubMed     Text format     Abstract available


  10. GOEY KK, 't Lam-Boer J, de Wilt JH, Punt CJ, et al
    Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
    Eur J Cancer. 2016;69:166-177.
    PubMed     Text format     Abstract available


    October 2016
  11. BOUCHAHDA M, Boige V, Smith D, Karaboue A, et al
    Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Eur J Cancer. 2016;68:163-172.
    PubMed     Text format     Abstract available


  12. PRICE T, Kim TW, Li J, Cascinu S, et al
    Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Eur J Cancer. 2016;68:51-59.
    PubMed     Text format     Abstract available


  13. ZHAO Y, Fan D, Ru B, Cheng KW, et al
    6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Eur J Cancer. 2016;68:38-50.
    PubMed     Text format     Abstract available


    September 2016
  14. HEINEMANN V, Rivera F, O'Neil BH, Stintzing S, et al
    A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2016;67:11-20.
    PubMed     Text format     Abstract available


    August 2016
  15. MOL L, Ottevanger PB, Koopman M, Punt CJ, et al
    The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
    Eur J Cancer. 2016;66:138-143.
    PubMed     Text format     Abstract available


    July 2016
  16. CABALLERO-BANOS M, Benitez-Ribas D, Tabera J, Varea S, et al
    Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
    Eur J Cancer. 2016;64:167-174.
    PubMed     Text format     Abstract available


    June 2016
  17. BREUGOM AJ, Bastiaannet E, Boelens PG, Iversen LH, et al
    Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.
    Eur J Cancer. 2016;63:110-117.
    PubMed     Text format     Abstract available


    May 2016
  18. LOGANADANE G, Servagi-Vernat S, Schernberg A, Schlienger M, et al
    Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series.
    Eur J Cancer. 2016;58:83-9.
    PubMed     Text format     Abstract available


    April 2016
  19. VAN ERNING FN, Razenberg LG, Lemmens VE, Creemers GJ, et al
    Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
    Eur J Cancer. 2016;61:1-10.
    PubMed     Text format     Abstract available


    March 2016
  20. DE RIDDER JA, van der Stok EP, Mekenkamp LJ, Wiering B, et al
    Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection.
    Eur J Cancer. 2016;59:13-21.
    PubMed     Text format     Abstract available


  21. MCLACHLAN SA, Fisher RJ, Zalcberg J, Solomon M, et al
    The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).
    Eur J Cancer. 2016;55:15-26.
    PubMed     Text format     Abstract available


  22. HAAGENSEN EJ, Thomas HD, Mudd C, Tsonou E, et al
    Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Eur J Cancer. 2016;56:69-76.
    PubMed     Text format     Abstract available


    January 2016
  23. ROWLAND A, Dias MM, Wiese MD, Kichenadasse G, et al
    Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Eur J Cancer. 2016;55:122-130.
    PubMed     Text format     Abstract available


  24. HELDER-WOOLDERINK JM, Blok EA, Vasen HF, Hollema H, et al
    Ovarian cancer in Lynch syndrome; a systematic review.
    Eur J Cancer. 2016;55:65-73.
    PubMed     Text format     Abstract available


  25. FORMICA V, Formica D, Formica G
    The 'death pace' in the CO.17 trial.
    Eur J Cancer. 2016;53:1-4.
    PubMed     Text format     Abstract available


  26. CASHIN PH, Mahteme H, Spang N, Syk I, et al
    Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    Eur J Cancer. 2016;53:155-62.
    PubMed     Text format     Abstract available


  27. NOREN A, Eriksson HG, Olsson LI
    Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study.
    Eur J Cancer. 2016;53:105-14.
    PubMed     Text format     Abstract available


    December 2015
  28. LEON O, Guren MG, Radu C, Gunnlaugsson A, et al
    Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Eur J Cancer. 2015;51:2740-6.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: